UK’s CMA Fines Four On Nortriptyline

Accord, Alissa, Lexon And King Fined Over £3.4m In Total

Four firms – Accord, Alissa, Lexon and King – have been fined by the UK’s Competition and Markets Authority over price-fixing and information-sharing activities related to the supply of nortriptyline.

CMA
The CMA has fined four firms over nortriptyline market sharing and information exchange • Source: Shutterstock

Four firms – Accord, Alissa Healthcare Research, Lexon and King Pharmaceutials – have been fined by the UK’s Competition and Markets Authority over price-fixing and information-sharing activities related to the supply of nortriptyline.

The fines imposed by the CMA come to more than £3.4m ($4.4m) in total, with a further £1m payment to...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Regulation

Test Regulatory Recap: Ireland To See Earlier Off-Patent Medicines Launches As A State Deal Passes

 

Also, Latest News From Europe, Canada, Saudi Arabia, Finland, China, And The US

Sawai Outlook Improves But Japanese Generics Continue To Suffer Under NHI Price Cuts

 
• By 

Japanese generics giant Sawai appears to be turning a corner, but the impact of National Health Insurance pricing revisions continues to hold the firm – and the rest of the country’s generics industry – back.

Kashiv Finishes Patient Recruitment In Late Stage Xolair Biosimilar Trial

 
• By 

Following on from its recently announced US licensing deal with Amneal over its Xolair biosimilar, Kashiv has finished patient recruitment for a trial for the omalizumab candidate, paving the way for submissions.

More from Policy & Regulation

Overseas API Manufacturing Identified As Key Vulnerability In US Supply Chain

After US President Joe Biden launched a review of the country’s API supply chain, the task force has reported back with key vulnerabilities that contribute to drug shortages and supply risks during a global public health emergency. According to the report, the lack of geographic diversity and dependence on foreign nations and anti-competitive actions by foreign nations are key areas of concern.

Sawai Outlook Improves But Japanese Generics Continue To Suffer Under NHI Price Cuts

 
• By 

Japanese generics giant Sawai appears to be turning a corner, but the impact of National Health Insurance pricing revisions continues to hold the firm – and the rest of the country’s generics industry – back.

Biden Launches Effort To Strengthen US Pharmaceutical Supply Chain

 
• By 

A fresh executive order from US president Joe Biden calls for short-term and long-term study, broad consultation, and co-ordination with allies on the domestic supply chain.